• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global and Japan CD Antigen Cancer Therapy Market Insights, Forecast to 2026

report cover
  • 2 September 2020
  • Healthcare
  • 140 Pages
  • Report Code: 24LS-21242
  • Formate :   
Download FREE Report Sample Download PDF File

CD Antigen Cancer Therapy -MARKET ADVISORY SERVICES

CD Antigen Cancer Therapy market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global CD Antigen Cancer Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the CD Antigen Cancer Therapy market is segmented into
Monoclonal Antibodies
Antibody-Drug-Conjugates
Tri-Functional and Bi-Specific T-Cell Engager Antibodies
Other

Segment by Application, the CD Antigen Cancer Therapy market is segmented into
Hospitals
Clinics
Other

Regional and Country-level Analysis
The CD Antigen Cancer Therapy market is analysed and market size information is provided by regions (countries).
The key regions covered in the CD Antigen Cancer Therapy market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and CD Antigen Cancer Therapy Market Share Analysis
CD Antigen Cancer Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in CD Antigen Cancer Therapy business, the date to enter into the CD Antigen Cancer Therapy market, CD Antigen Cancer Therapy product introduction, recent developments, etc.
The major vendors covered:
AryoGen Biopharma
Biocad
Biogen Idec
Celltrion
Genentech
Genmab
GLYCART Biotechnology
Hetero Drugs
mAbxience
MedImmune
Merck
Sandoz
UCB
1 Study Coverage
1.1 CD Antigen Cancer Therapy Product Introduction
1.2 Market Segments
1.3 Key CD Antigen Cancer Therapy Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Type
1.4.2 Monoclonal Antibodies
1.4.3 Antibody-Drug-Conjugates
1.4.4 Tri-Functional and Bi-Specific T-Cell Engager Antibodies
1.4.5 Other
1.5 Market by Application
1.5.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global CD Antigen Cancer Therapy Market Size, Estimates and Forecasts
2.1.1 Global CD Antigen Cancer Therapy Revenue 2015-2026
2.1.2 Global CD Antigen Cancer Therapy Sales 2015-2026
2.2 Global CD Antigen Cancer Therapy, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 CD Antigen Cancer Therapy Historical Market Size by Region (2015-2020)
2.3.1 Global CD Antigen Cancer Therapy Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global CD Antigen Cancer Therapy Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 CD Antigen Cancer Therapy Market Estimates and Projections by Region (2021-2026)
2.4.1 Global CD Antigen Cancer Therapy Sales Forecast by Region (2021-2026)
2.4.2 Global CD Antigen Cancer Therapy Revenue Forecast by Region (2021-2026)

3 Global CD Antigen Cancer Therapy Competitor Landscape by Players
3.1 Global Top CD Antigen Cancer Therapy Sales by Manufacturers
3.1.1 Global CD Antigen Cancer Therapy Sales by Manufacturers (2015-2020)
3.1.2 Global CD Antigen Cancer Therapy Sales Market Share by Manufacturers (2015-2020)
3.2 Global CD Antigen Cancer Therapy Manufacturers by Revenue
3.2.1 Global CD Antigen Cancer Therapy Revenue by Manufacturers (2015-2020)
3.2.2 Global CD Antigen Cancer Therapy Revenue Share by Manufacturers (2015-2020)
3.2.3 Global CD Antigen Cancer Therapy Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by CD Antigen Cancer Therapy Revenue in 2019
3.2.5 Global CD Antigen Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global CD Antigen Cancer Therapy Price by Manufacturers
3.4 Global CD Antigen Cancer Therapy Manufacturing Base Distribution, Product Types
3.4.1 CD Antigen Cancer Therapy Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers CD Antigen Cancer Therapy Product Type
3.4.3 Date of International Manufacturers Enter into CD Antigen Cancer Therapy Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global CD Antigen Cancer Therapy Market Size by Type (2015-2020)
4.1.1 Global CD Antigen Cancer Therapy Sales by Type (2015-2020)
4.1.2 Global CD Antigen Cancer Therapy Revenue by Type (2015-2020)
4.1.3 CD Antigen Cancer Therapy Average Selling Price (ASP) by Type (2015-2026)
4.2 Global CD Antigen Cancer Therapy Market Size Forecast by Type (2021-2026)
4.2.1 Global CD Antigen Cancer Therapy Sales Forecast by Type (2021-2026)
4.2.2 Global CD Antigen Cancer Therapy Revenue Forecast by Type (2021-2026)
4.2.3 CD Antigen Cancer Therapy Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global CD Antigen Cancer Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global CD Antigen Cancer Therapy Market Size by Application (2015-2020)
5.1.1 Global CD Antigen Cancer Therapy Sales by Application (2015-2020)
5.1.2 Global CD Antigen Cancer Therapy Revenue by Application (2015-2020)
5.1.3 CD Antigen Cancer Therapy Price by Application (2015-2020)
5.2 CD Antigen Cancer Therapy Market Size Forecast by Application (2021-2026)
5.2.1 Global CD Antigen Cancer Therapy Sales Forecast by Application (2021-2026)
5.2.2 Global CD Antigen Cancer Therapy Revenue Forecast by Application (2021-2026)
5.2.3 Global CD Antigen Cancer Therapy Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application
6.1 Japan CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
6.1.1 Japan CD Antigen Cancer Therapy Sales YoY Growth 2015-2026
6.1.2 Japan CD Antigen Cancer Therapy Revenue YoY Growth 2015-2026
6.1.3 Japan CD Antigen Cancer Therapy Market Share in Global Market 2015-2026
6.2 Japan CD Antigen Cancer Therapy Market Size by Players (International and Local Players)
6.2.1 Japan Top CD Antigen Cancer Therapy Players by Sales (2015-2020)
6.2.2 Japan Top CD Antigen Cancer Therapy Players by Revenue (2015-2020)
6.3 Japan CD Antigen Cancer Therapy Historic Market Review by Type (2015-2020)
6.3.1 Japan CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
6.3.2 Japan CD Antigen Cancer Therapy Revenue Market Share by Type (2015-2020)
6.3.3 Japan CD Antigen Cancer Therapy Price by Type (2015-2020)
6.4 Japan CD Antigen Cancer Therapy Market Estimates and Forecasts by Type (2021-2026)
6.4.1 Japan CD Antigen Cancer Therapy Sales Forecast by Type (2021-2026)
6.4.2 Japan CD Antigen Cancer Therapy Revenue Forecast by Type (2021-2026)
6.4.3 Japan CD Antigen Cancer Therapy Price Forecast by Type (2021-2026)
6.5 Japan CD Antigen Cancer Therapy Historic Market Review by Application (2015-2020)
6.5.1 Japan CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
6.5.2 Japan CD Antigen Cancer Therapy Revenue Market Share by Application (2015-2020)
6.5.3 Japan CD Antigen Cancer Therapy Price by Application (2015-2020)
6.6 Japan CD Antigen Cancer Therapy Market Estimates and Forecasts by Application (2021-2026)
6.6.1 Japan CD Antigen Cancer Therapy Sales Forecast by Application (2021-2026)
6.6.2 Japan CD Antigen Cancer Therapy Revenue Forecast by Application (2021-2026)
6.6.3 Japan CD Antigen Cancer Therapy Price Forecast by Application (2021-2026)

7 North America
7.1 North America CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
7.2 North America CD Antigen Cancer Therapy Market Facts & Figures by Country
7.2.1 North America CD Antigen Cancer Therapy Sales by Country (2015-2020)
7.2.2 North America CD Antigen Cancer Therapy Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada

8 Europe
8.1 Europe CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
8.2 Europe CD Antigen Cancer Therapy Market Facts & Figures by Country
8.2.1 Europe CD Antigen Cancer Therapy Sales by Country
8.2.2 Europe CD Antigen Cancer Therapy Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia

9 Asia Pacific
9.1 Asia Pacific CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
9.2 Asia Pacific CD Antigen Cancer Therapy Market Facts & Figures by Country
9.2.1 Asia Pacific CD Antigen Cancer Therapy Sales by Region (2015-2020)
9.2.2 Asia Pacific CD Antigen Cancer Therapy Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam

10 Latin America
10.1 Latin America CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
10.2 Latin America CD Antigen Cancer Therapy Market Facts & Figures by Country
10.2.1 Latin America CD Antigen Cancer Therapy Sales by Country
10.2.2 Latin America CD Antigen Cancer Therapy Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa CD Antigen Cancer Therapy Market Size YoY Growth 2015-2026
11.2 Middle East and Africa CD Antigen Cancer Therapy Market Facts & Figures by Country
11.2.1 Middle East and Africa CD Antigen Cancer Therapy Sales by Country
11.2.2 Middle East and Africa CD Antigen Cancer Therapy Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 AryoGen Biopharma
12.1.1 AryoGen Biopharma Corporation Information
12.1.2 AryoGen Biopharma Description and Business Overview
12.1.3 AryoGen Biopharma Sales, Revenue and Gross Margin (2015-2020)
12.1.4 AryoGen Biopharma CD Antigen Cancer Therapy Products Offered
12.1.5 AryoGen Biopharma Recent Development
12.2 Biocad
12.2.1 Biocad Corporation Information
12.2.2 Biocad Description and Business Overview
12.2.3 Biocad Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Biocad CD Antigen Cancer Therapy Products Offered
12.2.5 Biocad Recent Development
12.3 Biogen Idec
12.3.1 Biogen Idec Corporation Information
12.3.2 Biogen Idec Description and Business Overview
12.3.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Biogen Idec CD Antigen Cancer Therapy Products Offered
12.3.5 Biogen Idec Recent Development
12.4 Celltrion
12.4.1 Celltrion Corporation Information
12.4.2 Celltrion Description and Business Overview
12.4.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Celltrion CD Antigen Cancer Therapy Products Offered
12.4.5 Celltrion Recent Development
12.5 Genentech
12.5.1 Genentech Corporation Information
12.5.2 Genentech Description and Business Overview
12.5.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Genentech CD Antigen Cancer Therapy Products Offered
12.5.5 Genentech Recent Development
12.6 Genmab
12.6.1 Genmab Corporation Information
12.6.2 Genmab Description and Business Overview
12.6.3 Genmab Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Genmab CD Antigen Cancer Therapy Products Offered
12.6.5 Genmab Recent Development
12.7 GLYCART Biotechnology
12.7.1 GLYCART Biotechnology Corporation Information
12.7.2 GLYCART Biotechnology Description and Business Overview
12.7.3 GLYCART Biotechnology Sales, Revenue and Gross Margin (2015-2020)
12.7.4 GLYCART Biotechnology CD Antigen Cancer Therapy Products Offered
12.7.5 GLYCART Biotechnology Recent Development
12.8 Hetero Drugs
12.8.1 Hetero Drugs Corporation Information
12.8.2 Hetero Drugs Description and Business Overview
12.8.3 Hetero Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Hetero Drugs CD Antigen Cancer Therapy Products Offered
12.8.5 Hetero Drugs Recent Development
12.9 mAbxience
12.9.1 mAbxience Corporation Information
12.9.2 mAbxience Description and Business Overview
12.9.3 mAbxience Sales, Revenue and Gross Margin (2015-2020)
12.9.4 mAbxience CD Antigen Cancer Therapy Products Offered
12.9.5 mAbxience Recent Development
12.10 MedImmune
12.10.1 MedImmune Corporation Information
12.10.2 MedImmune Description and Business Overview
12.10.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
12.10.4 MedImmune CD Antigen Cancer Therapy Products Offered
12.10.5 MedImmune Recent Development
12.11 AryoGen Biopharma
12.11.1 AryoGen Biopharma Corporation Information
12.11.2 AryoGen Biopharma Description and Business Overview
12.11.3 AryoGen Biopharma Sales, Revenue and Gross Margin (2015-2020)
12.11.4 AryoGen Biopharma CD Antigen Cancer Therapy Products Offered
12.11.5 AryoGen Biopharma Recent Development
12.12 Sandoz
12.12.1 Sandoz Corporation Information
12.12.2 Sandoz Description and Business Overview
12.12.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Sandoz Products Offered
12.12.5 Sandoz Recent Development
12.13 UCB
12.13.1 UCB Corporation Information
12.13.2 UCB Description and Business Overview
12.13.3 UCB Sales, Revenue and Gross Margin (2015-2020)
12.13.4 UCB Products Offered
12.13.5 UCB Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key CD Antigen Cancer Therapy Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 CD Antigen Cancer Therapy Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables

Table 1. CD Antigen Cancer Therapy Market Segments

Table 2. Ranking of Global Top CD Antigen Cancer Therapy Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global CD Antigen Cancer Therapy Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)

Table 4. Major Manufacturers of Monoclonal Antibodies

Table 5. Major Manufacturers of Antibody-Drug-Conjugates

Table 6. Major Manufacturers of Tri-Functional and Bi-Specific T-Cell Engager Antibodies

Table 7. Major Manufacturers of Other

Table 8. Global CD Antigen Cancer Therapy Market Size Growth Rate by Application 2020-2026 (K Units)

Table 9. Global CD Antigen Cancer Therapy Market Size by Region (K Units) & (US$ Million): 2020 VS 2026

Table 10. Global CD Antigen Cancer Therapy Sales by Regions 2015-2020 (K Units)

Table 11. Global CD Antigen Cancer Therapy Sales Market Share by Regions (2015-2020)

Table 12. Global CD Antigen Cancer Therapy Revenue by Regions 2015-2020 (US$ Million)

Table 13. Global CD Antigen Cancer Therapy Sales Forecast by Region (2021-2026) (K Units)

Table 14. Global CD Antigen Cancer Therapy Sales by Manufacturers (2015-2020) (K Units)

Table 15. Global CD Antigen Cancer Therapy Sales Share by Manufacturers (2015-2020)

Table 16. Global CD Antigen Cancer Therapy Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 17. Global CD Antigen Cancer Therapy by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CD Antigen Cancer Therapy as of 2019)

Table 18. CD Antigen Cancer Therapy Revenue by Manufacturers (2015-2020) (US$ Million)

Table 19. CD Antigen Cancer Therapy Revenue Share by Manufacturers (2015-2020)

Table 20. Key Manufacturers CD Antigen Cancer Therapy Price (2015-2020) (USD/Unit)

Table 21. CD Antigen Cancer Therapy Manufacturers Manufacturing Base Distribution and Headquarters

Table 22. Manufacturers CD Antigen Cancer Therapy Product Type

Table 23. Date of International Manufacturers Enter into CD Antigen Cancer Therapy Market

Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 25. Global CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)

Table 26. Global CD Antigen Cancer Therapy Sales Share by Type (2015-2020)

Table 27. Global CD Antigen Cancer Therapy Revenue by Type (2015-2020) (US$ Million)

Table 28. Global CD Antigen Cancer Therapy Revenue Share by Type (2015-2020)

Table 29. CD Antigen Cancer Therapy Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)

Table 30. Global CD Antigen Cancer Therapy Sales Share by Type (2021-2026)

Table 31. Global CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)

Table 32. Global CD Antigen Cancer Therapy Sales Share by Application (2015-2020)

Table 33. Global CD Antigen Cancer Therapy Sales Share by Application (2021-2026)

Table 34. Global CD Antigen Cancer Therapy Sales Market Share Forecast by Application (2021-2026)

Table 35. Global CD Antigen Cancer Therapy Revenue by Application (2015-2020) (US$ Million)

Table 36. Global CD Antigen Cancer Therapy Revenue Market Share Forecast by Application (2021-2026)

Table 37. Japan CD Antigen Cancer Therapy Sales (K Units) of Key Companies (2015-2020)

Table 38. Japan CD Antigen Cancer Therapy Sales Share by Company (2015-2020)

Table 39. Japan CD Antigen Cancer Therapy Revenue (US$ Million) by Company (2015-2020)

Table 40. Japan CD Antigen Cancer Therapy Sales (K Units) by Type (2015-2020)

Table 41. Japan CD Antigen Cancer Therapy Sales Share by Type (2015-2020)

Table 42. Japan CD Antigen Cancer Therapy Revenue (US$ Million) Market Share by Type (2015-2020)

Table 43. Japan CD Antigen Cancer Therapy Price (K Units) by Type (2015-2020)

Table 44. Japan CD Antigen Cancer Therapy Sales (K Units) by Type (2021-2026)

Table 45. Japan CD Antigen Cancer Therapy Sales Share by Type (2021-2026)

Table 46. Japan CD Antigen Cancer Therapy Revenue (US$ Million) Market Share by Type (2021-2026)

Table 47. Japan CD Antigen Cancer Therapy Revenue Share by Type (2021-2026)

Table 48. Japan CD Antigen Cancer Therapy Price (K Units) by Type (2021-2026)

Table 49. Japan CD Antigen Cancer Therapy Sales (K Units) by Application (2015-2020)

Table 50. Japan CD Antigen Cancer Therapy Sales Share by Application (2015-2020)

Table 51. Japan CD Antigen Cancer Therapy Revenue (US$ Million) Market Share by Application (2015-2020)

Table 52. Japan CD Antigen Cancer Therapy Sales (K Units) by Application (2021-2026)

Table 53. Japan CD Antigen Cancer Therapy Sales Share by Application (2021-2026)

Table 54. Japan CD Antigen Cancer Therapy Revenue (US$ Million) Market Share by Application (2021-2026)

Table 55. Japan CD Antigen Cancer Therapy Revenue Share by Application (2021-2026)

Table 56. North America CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)

Table 57. North America CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)

Table 58. North America CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)

Table 59. North America CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)

Table 60. Europe CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)

Table 61. Europe CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)

Table 62. Europe CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)

Table 63. Europe CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)

Table 64. Asia Pacific CD Antigen Cancer Therapy Sales by Region (2015-2020) (K Units)

Table 65. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Region (2015-2020)

Table 66. Asia Pacific CD Antigen Cancer Therapy Revenue by Region (2015-2020) (US$ Million)

Table 67. Asia Pacific CD Antigen Cancer Therapy Revenue Market Share by Region (2015-2020)

Table 68. Latin America CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)

Table 69. Latin America CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)

Table 70. Latin Americaa CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)

Table 71. Latin America CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)

Table 72. Middle East and Africa CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)

Table 73. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)

Table 74. Middle East and Africa CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)

Table 75. Middle East and Africa CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)

Table 76. AryoGen Biopharma Corporation Information

Table 77. AryoGen Biopharma Description and Business Overview

Table 78. AryoGen Biopharma CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 79. AryoGen Biopharma CD Antigen Cancer Therapy Product

Table 80. AryoGen Biopharma Recent Development

Table 81. Biocad Corporation Information

Table 82. Biocad Description and Business Overview

Table 83. Biocad CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 84. Biocad Product

Table 85. Biocad Recent Development

Table 86. Biogen Idec Corporation Information

Table 87. Biogen Idec Description and Business Overview

Table 88. Biogen Idec CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 89. Biogen Idec Product

Table 90. Biogen Idec Recent Development

Table 91. Celltrion Corporation Information

Table 92. Celltrion Description and Business Overview

Table 93. Celltrion CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 94. Celltrion Product

Table 95. Celltrion Recent Development

Table 96. Genentech Corporation Information

Table 97. Genentech Description and Business Overview

Table 98. Genentech CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 99. Genentech Product

Table 100. Genentech Recent Development

Table 101. Genmab Corporation Information

Table 102. Genmab Description and Business Overview

Table 103. Genmab CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 104. Genmab Product

Table 105. Genmab Recent Development

Table 106. GLYCART Biotechnology Corporation Information

Table 107. GLYCART Biotechnology Description and Business Overview

Table 108. GLYCART Biotechnology CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 109. GLYCART Biotechnology Product

Table 110. GLYCART Biotechnology Recent Development

Table 111. Hetero Drugs Corporation Information

Table 112. Hetero Drugs Description and Business Overview

Table 113. Hetero Drugs CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 114. Hetero Drugs Product

Table 115. Hetero Drugs Recent Development

Table 116. mAbxience Corporation Information

Table 117. mAbxience Description and Business Overview

Table 118. mAbxience CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 119. mAbxience Product

Table 120. mAbxience Recent Development

Table 121. MedImmune Corporation Information

Table 122. MedImmune Description and Business Overview

Table 123. MedImmune CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 124. MedImmune Product

Table 125. MedImmune Recent Development

Table 126. Merck Corporation Information

Table 127. Merck Description and Business Overview

Table 128. Merck CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 129. Merck Product

Table 130. Merck Recent Development

Table 131. Sandoz Corporation Information

Table 132. Sandoz Description and Business Overview

Table 133. Sandoz CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 134. Sandoz Product

Table 135. Sandoz Recent Development

Table 136. UCB Corporation Information

Table 137. UCB Description and Business Overview

Table 138. UCB CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 139. UCB Product

Table 140. UCB Recent Development

Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 142. Key Challenges

Table 143. Market Risks

Table 144. Main Points Interviewed from Key CD Antigen Cancer Therapy Players

Table 145. CD Antigen Cancer Therapy Customers List

Table 146. CD Antigen Cancer Therapy Distributors List

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

List of Figures

Figure 1. CD Antigen Cancer Therapy Product Picture

Figure 2. Global CD Antigen Cancer Therapy Sales Market Share by Type in 2020 & 2026

Figure 3. Monoclonal Antibodies Product Picture

Figure 4. Antibody-Drug-Conjugates Product Picture

Figure 5. Tri-Functional and Bi-Specific T-Cell Engager Antibodies Product Picture

Figure 6. Other Product Picture

Figure 7. Global CD Antigen Cancer Therapy Sales Market Share by Application in 2020 & 2026

Figure 8. Hospitals

Figure 9. Clinics

Figure 10. Other

Figure 11. CD Antigen Cancer Therapy Report Years Considered

Figure 12. Global CD Antigen Cancer Therapy Market Size 2015-2026 (US$ Million)

Figure 13. Global CD Antigen Cancer Therapy Sales 2015-2026 (K Units)

Figure 14. Global CD Antigen Cancer Therapy Market Size Market Share by Region: 2020 Versus 2026

Figure 15. Global CD Antigen Cancer Therapy Sales Market Share by Region (2015-2020)

Figure 16. Global CD Antigen Cancer Therapy Sales Market Share by Region in 2019

Figure 17. Global CD Antigen Cancer Therapy Revenue Market Share by Region (2015-2020)

Figure 18. Global CD Antigen Cancer Therapy Revenue Market Share by Region in 2019

Figure 19. Global CD Antigen Cancer Therapy Sales Share by Manufacturer in 2019

Figure 20. The Top 10 and 5 Players Market Share by CD Antigen Cancer Therapy Revenue in 2019

Figure 21. CD Antigen Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 22. Global CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)

Figure 23. Global CD Antigen Cancer Therapy Sales Market Share by Type in 2019

Figure 24. Global CD Antigen Cancer Therapy Revenue Market Share by Type (2015-2020)

Figure 25. Global CD Antigen Cancer Therapy Revenue Market Share by Type in 2019

Figure 26. Global CD Antigen Cancer Therapy Market Share by Price Range (2015-2020)

Figure 27. Global CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)

Figure 28. Global CD Antigen Cancer Therapy Sales Market Share by Application in 2019

Figure 29. Global CD Antigen Cancer Therapy Revenue Market Share by Application (2015-2020)

Figure 30. Global CD Antigen Cancer Therapy Revenue Market Share by Application in 2019

Figure 31. Japan CD Antigen Cancer Therapy Sales Growth Rate 2015-2026 (K Units)

Figure 32. Japan CD Antigen Cancer Therapy Revenue Growth Rate 2015-2026 (US$ Million)

Figure 33. Japan CD Antigen Cancer Therapy Market Share in Global Market 2015-2026

Figure 34. Japan 5 and 10 Largest CD Antigen Cancer Therapy Players Market Share by Revenue in CD Antigen Cancer Therapy in 2019

Figure 35. Japan CD Antigen Cancer Therapy Revenue Share by Type (2015-2020)

Figure 36. Japan CD Antigen Cancer Therapy Revenue Growth Rate by Type in 2015 & 2019

Figure 37. Japan CD Antigen Cancer Therapy Revenue Share by Application (2015-2020)

Figure 38. Japan CD Antigen Cancer Therapy Revenue Growth Rate by Application in 2015 & 2019

Figure 39. North America CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)

Figure 40. North America CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)

Figure 41. North America CD Antigen Cancer Therapy Sales Market Share by Country in 2019

Figure 42. North America CD Antigen Cancer Therapy Revenue Market Share by Country in 2019

Figure 43. U.S. CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 44. U.S. CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 45. Canada CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 46. Canada CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 47. Europe CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)

Figure 48. Europe CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)

Figure 49. Europe CD Antigen Cancer Therapy Sales Market Share by Country in 2019

Figure 50. Europe CD Antigen Cancer Therapy Revenue Market Share by Country in 2019

Figure 51. Germany CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 52. Germany CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 53. France CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 54. France CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 55. U.K. CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 56. U.K. CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 57. Italy CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 58. Italy CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 59. Russia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 60. Russia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 61. Asia Pacific CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)

Figure 62. Asia Pacific CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)

Figure 63. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Region in 2019

Figure 64. Asia Pacific CD Antigen Cancer Therapy Revenue Market Share by Region in 2019

Figure 65. China CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 66. China CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 67. Japan CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 68. Japan CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 69. South Korea CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 70. South Korea CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 71. India CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 72. India CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 73. Australia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 74. Australia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 75. Taiwan CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 76. Taiwan CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 77. Indonesia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 78. Indonesia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 79. Thailand CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 80. Thailand CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 81. Malaysia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 82. Malaysia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 83. Philippines CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 84. Philippines CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 85. Vietnam CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 86. Vietnam CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 87. Latin America CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)

Figure 88. Latin America CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)

Figure 89. Latin America CD Antigen Cancer Therapy Sales Market Share by Country in 2019

Figure 90. Latin America CD Antigen Cancer Therapy Revenue Market Share by Country in 2019

Figure 91. Mexico CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 92. Mexico CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 93. Brazil CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 94. Brazil CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 95. Argentina CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 96. Argentina CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 97. Middle East and Africa CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)

Figure 98. Middle East and Africa CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)

Figure 99. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Country in 2019

Figure 100. Middle East and Africa CD Antigen Cancer Therapy Revenue Market Share by Country in 2019

Figure 101. Turkey CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 102. Turkey CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 103. Saudi Arabia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 104. Saudi Arabia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 105. U.A.E CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)

Figure 106. U.A.E CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)

Figure 107. Porter's Five Forces Analysis

Figure 108. CD Antigen Cancer Therapy Value Chain

Figure 109. Channels of Distribution

Figure 110. Distributors Profiles

Figure 111. Bottom-up and Top-down Approaches for This Report

Figure 112. Data Triangulation

Figure 113. Key Executives Interviewed

AryoGen Biopharma

Biocad

Biogen Idec

Celltrion

Genentech

Genmab

GLYCART Biotechnology

Hetero Drugs

mAbxience

MedImmune

Merck

Sandoz

UCB

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3120

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase